Cardiac Rehabilitation for COVID-19

Phase-Based Progress Estimates
University of California, San Francisco, San Francisco, CA
COVID-19+1 More
Cardiac Rehabilitation - Behavioral
All Sexes
What conditions do you have?

Study Summary

The goal of this proof-of-concept clinical trial is to determine whether cardiac rehabilitation improves exercise capacity and chronotropic (heart rate) response to exercise among people with Long COVID. The study will include individuals with confirmed SARS-CoV-2 infection, symptoms not present prior to COVID-19 that are persistent for at least 3 months after acute infection ("Long COVID"), and who have reduced exercise capacity less than predicted and reduced heart rate response during cardiopulmonary exercise testing (CPET). In addition to the primary outcome of change in peak VO2, secondary outcomes will include change in symptoms including autonomic symptoms (COMPASS-31), anxiety (GAD-7), depression (PHQ-9), endothelial function with brachial artery flow-mediated dilation, and satisfaction (net-promotor score).

Eligible Conditions

  • Long COVID
  • COVID-19

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 12 Secondary · Reporting Duration: 12 weeks

12 weeks
Net Promotor Score
Number of Cardiac Rehabilitation sessions attended
Baseline and 12 weeks
Change in Composite Autonomic Symptom Scale-31 (Compass 31) Score
Change in Generalized Anxiety Disorder Screener (GAD-7) Score
Change in Inflammation
Change in Number of Long COVID symptoms
Change in Patient Health Questionnaire-9 (PHQ-9) Score
Change in Peak VO2 (ml/kg/min)
Change in Peak VO2 (percent predicted)
Change in Proportion with peak VO2 less than 85% predicted
Change in Quality of life assessed with EuroQol (EQ-5D) Visual Analogue Scale
Change in Short Form Survey (SF-36) Score
Change in adjusted heart rate reserve
Change in flow mediated dilation of the brachial artery

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Cardiac Rehabilitation
1 of 1
Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Cardiac Rehabilitation · No Placebo Group · N/A

Cardiac Rehabilitation
Experimental Group · 1 Intervention: Cardiac Rehabilitation · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiac Rehabilitation
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks
Closest Location: University of California, San Francisco · San Francisco, CA
Photo of San Francisco  1Photo of San Francisco  2Photo of San Francisco  3
2008First Recorded Clinical Trial
5 TrialsResearching COVID-19
688 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be between the ages of 18 and 50 years old.
You have been previously documented to have SARS-CoV-2 RNA positivity, documented positive antigen testing, or documented positive nucleocapsid antibody
Presence of persistent symptoms, defined as at least one COVID-attributed symptom newly present during acute illness or worse than baseline and reported to still be present for at least 90 days following symptom onset.
You are willing and able to actively participate in cardiac rehabilitation.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.